Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H30O3 |
| Molecular Weight | 306.4397 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])[C@@H](O)C[C@@]4([H])C[C@@H](O)CC[C@]34C
InChI
InChIKey=VFPMCLQMAUVEHD-UCPSWNCLSA-N
InChI=1S/C19H30O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h11-15,17,20-21H,3-10H2,1-2H3/t11-,12+,13+,14+,15+,17+,18+,19+/m1/s1
| Molecular Formula | C19H30O3 |
| Molecular Weight | 306.4397 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:03:28 UTC 2023
by
admin
on
Sat Dec 16 11:03:28 UTC 2023
|
| Record UNII |
OCP3E5KD08
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7β-Hydroxyepiandrosterone
Created by
admin on Sat Dec 16 11:03:28 UTC 2023 , Edited by admin on Sat Dec 16 11:03:28 UTC 2023
|
PRIMARY | |||
|
9836181
Created by
admin on Sat Dec 16 11:03:28 UTC 2023 , Edited by admin on Sat Dec 16 11:03:28 UTC 2023
|
PRIMARY | |||
|
DB06622
Created by
admin on Sat Dec 16 11:03:28 UTC 2023 , Edited by admin on Sat Dec 16 11:03:28 UTC 2023
|
PRIMARY | |||
|
25848-69-5
Created by
admin on Sat Dec 16 11:03:28 UTC 2023 , Edited by admin on Sat Dec 16 11:03:28 UTC 2023
|
PRIMARY | |||
|
DTXSID701293235
Created by
admin on Sat Dec 16 11:03:28 UTC 2023 , Edited by admin on Sat Dec 16 11:03:28 UTC 2023
|
PRIMARY | |||
|
OCP3E5KD08
Created by
admin on Sat Dec 16 11:03:28 UTC 2023 , Edited by admin on Sat Dec 16 11:03:28 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
IN VITRO
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Although all dose levels of 7beta-hydroxy-EpiA reduced PGE(2) production, only the lowest dose (0.01mg/kg) of the steroid completely prevented colitis damage and tissue inflammation. 7beta-Hydroxy-EpiA pre-treatment prevents the occurrence of DSS-induced colitis through a shift from PGE(2) to PGD(2) production, associated with an early but transient increase in COX-2 expression and a sustained increase in the production of the anti-inflammatory prostaglandin 15d-PGJ(2).
|
||
|
ACTIVE MOIETY |
Class: 17 ketosteroid, Androstanol, Neuroprotectant, Testosterone congener; Mechanism of Action: Antioxidant and Glucocorticoid receptor antagonist; Highest Development Phase: Discontinued for Alzheimer's disease, Inflammatory bowel disease, Psoriasis and Rheumatoid arthriti; Most Recent Event: 14 Sep 2010 HF 0220 is available for licensing worldwide as of 10 Sep 2010. http:///www.newron.com
|
||
|
ACTIVE MOIETY |
Intracerebroventricular administration of ethylcholine aziridinium (AF64A) caused cholinergic damage in the septum, and glial lesions in the lateral septal nucleus and in the lateral zones of the hippocampus. These effects were almost completely prevented when animals were treated subcutaneously (b.i.d.) for 10 days with 0.1 mg/kg 7beta-hydroxy epiandrosterone. These findings indicate that 7beta-hydroxy epiandrosterone has powerful cytoprotective effects suggesting that (a) this neurosteroid may have therapeutic potential in various neurodegenerative conditions such as Alzheimer's disease, and (b) 7beta-hydroxy steroids may constitute a novel class of endogenous neuroprotective agents.
|
